NASDAQ:CRTX Cortexyme Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $57.30 +1.70 (+3.06 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$55.77Now: $57.30▼$57.6650-Day Range$39.85MA: $44.44▼$55.6052-Week Range$20.14Now: $57.30▼$73.84Volume550,438 shsAverage Volume139,811 shsMarket Capitalization$1.69 billionP/E RatioN/ADividend YieldN/ABeta1.45 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingCortexyme has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $68.33, Cortexyme has a forecasted upside of 19.3% from its current price of $57.30.Amount of Analyst CoverageCortexyme has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesCortexyme has received 143 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCortexyme has received 119 “underperform” votes. (Add your “underperform” vote.)Community SentimentCortexyme has received 54.58% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cortexyme and other stocks. Vote “Outperform” if you believe CRTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCortexyme does not currently pay a dividend.Dividend GrowthCortexyme does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cortexyme insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 19.80% of the stock of Cortexyme is held by insiders.Percentage Held by Institutions51.71% of the stock of Cortexyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cortexyme are expected to remain at ($2.53) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cortexyme is -28.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cortexyme is -28.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCortexyme has a P/B Ratio of 13.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.24 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryHealth Care Technology SectorMedical Current SymbolNASDAQ:CRTX Previous Symbol CUSIP21924P10 CIK1145404 Webwww.cortexyme.com Phone415-910-5717Debt Debt-to-Equity RatioN/A Current Ratio11.07 Quick Ratio11.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.30 per share Price / Book13.33Profitability EPS (Most Recent Fiscal Year)($1.94) Net Income$-36,980,000.00 Net MarginsN/A Return on Equity-34.24% Return on Assets-32.21%Miscellaneous Employees16 Outstanding Shares29,488,000Market Cap$1.69 billion Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $57.30 +1.70 (+3.06 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CRTX News and Ratings via Email Sign-up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Cortexyme (NASDAQ:CRTX) Frequently Asked Questions How has Cortexyme's stock been impacted by COVID-19? Cortexyme's stock was trading at $37.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CRTX shares have increased by 54.8% and is now trading at $57.30. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Cortexyme? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cortexyme. When is Cortexyme's next earnings date? Cortexyme is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Cortexyme. How were Cortexyme's earnings last quarter? Cortexyme, Inc. (NASDAQ:CRTX) posted its earnings results on Monday, August, 17th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.02. View Cortexyme's earnings history. What price target have analysts set for CRTX? 3 brokerages have issued twelve-month target prices for Cortexyme's stock. Their forecasts range from $59.00 to $76.00. On average, they expect Cortexyme's stock price to reach $68.33 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price. View analysts' price targets for Cortexyme. Who are some of Cortexyme's key competitors? Some companies that are related to Cortexyme include Cerner (CERN), Omnicell (OMCL), HMS (HMSY), Allscripts Healthcare Solutions (MDRX), Vocera Communications (VCRA), HealthStream (HSTM) and Computer Programs & Systems (CPSI). View all competitors. What other stocks do shareholders of Cortexyme own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include ADMA Biologics (ADMA), Gran Tierra Energy (GTE), BioNano Genomics (BNGO), DHT (DHT), EnLink Midstream (ENLC), Golar LNG Partners (GMLP), Matinas BioPharma (MTNB), OrganiGram (OGI), Pennsylvania R.E.I.T. (PEI) and Tilly's (TLYS). Who are Cortexyme's key executives? Cortexyme's management team includes the following people: Ms. Casey C. Lynch, Co-Founder, Chairman, Pres & CEO (Age 45)Mr. Stephen S. Dominy, Co-Founder, Chief Scientific Officer & Director (Age 63)Ms. Kristen Gafric, Co-Founder, Sr. VP of Legal & Admin. and Sec. (Age 43)Mr. Christopher P. Lowe, CFO & Treasurer (Age 48)Dr. Michael J. Detke, Chief Medical Officer (Age 52) When did Cortexyme IPO? (CRTX) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers. What is Cortexyme's stock symbol? Cortexyme trades on the NASDAQ under the ticker symbol "CRTX." Who are Cortexyme's major shareholders? Cortexyme's stock is owned by a variety of institutional and retail investors. Top institutional investors include EPIQ Capital Group LLC (11.36%), Vanguard Group Inc. (2.04%), Bank of New York Mellon Corp (0.26%), Nuveen Asset Management LLC (0.25%), Marshall Wace North America L.P. (0.20%) and Charles Schwab Investment Management Inc. (0.19%). Company insiders that own Cortexyme stock include David Lamond, Epiq Capital Group, Llc and Pfizer Inc. View institutional ownership trends for Cortexyme. Which major investors are selling Cortexyme stock? CRTX stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., UBS Group AG, Virtus ETF Advisers LLC, and Bank of America Corp DE. View insider buying and selling activity for Cortexyme. Which major investors are buying Cortexyme stock? CRTX stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., EPIQ Capital Group LLC, Goldman Sachs Group Inc., SG Americas Securities LLC, Swiss National Bank, Nuveen Asset Management LLC, Marshall Wace North America L.P., and Bank of New York Mellon Corp. Company insiders that have bought Cortexyme stock in the last two years include David Lamond, Epiq Capital Group, Llc, and Pfizer Inc. View insider buying and selling activity for Cortexyme. How do I buy shares of Cortexyme? Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cortexyme's stock price today? One share of CRTX stock can currently be purchased for approximately $57.30. How big of a company is Cortexyme? Cortexyme has a market capitalization of $1.69 billion. The biopharmaceutical company earns $-36,980,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. Cortexyme employs 16 workers across the globe. What is Cortexyme's official website? The official website for Cortexyme is www.cortexyme.com. How can I contact Cortexyme? Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
